|
|
2.
|
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. MedStar authors:
Year: 2018
Citation: - New England Journal of Medicine. 379(12):1107-1117, 2018 09 20.
Institution: - MedStar Heart & Vascular Institute
Medline publication type:
All authors: - Bohula EA, Bonaca MP, Brown C, Budaj A, CAMELLIA-TIMI 61 Steering Committee and Investigators, Dhadda S, Fanola CL, Francis B, Garcia-Castillo A, Gupta M, Im K, Inzucchi SE, Keech AC, Kuder J, Leiter LA, McGuire DK, Miao W, Patel T, Perdomo C, Qamar A, Ruff CT, Sabatine MS, Scirica BM, Smith SR, Weissman NJ, White HD, Wiviott SD
|
|
|
3.
|
Neuropsychiatric safety with liraglutide 3.0mg for weight management: results from randomized controlled phase 2 and 3a trials. MedStar authors:
Year: 2017
Citation: - Diabetes, Obesity & Metabolism. 19(11):1529-1536, 2017 Nov.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Astrup A, Brett J, Cancino A, Kushner R, Lau DC, O'Neil PM, Satiety and Clinical Adiposity - Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups, Wadden TA, Wilding JP
|
